William Blair Remains Bullish on Genmab A/S (GMAB)
Genmab A/S (NASDAQ:GMAB) is one of the top most undervalued biotech stocks to buy now.
Genmab A/S (GMAB)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 3,454,378 | $71,367,449 | +153% | 0.05% |
| 2. | Renaissance Technologies Jim Simons | 2,766,750 | $57,161,055 | +23% | 0.08% |
| 3. | Marshall Wace LLP Paul Marshall And Ian Wace | 1,907,284 | $39,404,491 | -13% | 0.04% |
| 4. | Two Sigma Advisors John Overdeck And David Siegel | 1,821,000 | $37,621,860 | -8% | 0.08% |
| 5. | Woodline Partners Michael Rockefeller And Karl Kroeker | 493,506 | $10,195,834 | 0.05% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,166,021 | $65,410,001 | 0% | |
| 2. | 1,770,310 | $36,574,604 | 0.03% | |
| 3. | 1,744,769 | $36,046,928 | 0.25% | |
| 4. | 933,309 | $19,282,175 | 0% | |
| 5. | 924,343 | $19,096,950 | 0.02% |
News See All
10 Most Undervalued Biotech Stocks to Buy Now
On July 25, Salveen Richter, Goldman Sachs' lead biotech analyst, appeared on CNBC’s ‘Squawk Box’ to talk about the state of the biotech sector and what to expect from the earnings season, among...
Genmab A/S (NASDAQ:GMAB) Q2 2025 Earnings Call Transcript
Operator: Hello, and welcome to the Genmab First Half 2025 Financial Results Conference Call. As a reminder, this conference call is being recorded.
TD Cowen Maintains a Hold on Genmab A/S (GMAB)
Genmab A/S (NASDAQ:GMAB) is one of the most profitable biotech stocks to invest in now.
Genmab A/S (GMAB) Opens U.S. Hub in New Jersey to Drive Global Growth
Genmab A/S (NASDAQ:GMAB), a Danish biotech company founded in 1999, specializes in antibody-based therapies for cancer and serious diseases.
10 Most Profitable Biotech Stocks to Invest in Now
Jared Holz, Mizuho health care equity strategist, appeared on CNBC’s 'Power Lunch' on March 5 to talk about investing in biotech and the oversaturation in the sector.
Genmab (GMAB) Announced New Sales Figures for DARZALEX
Genmab A/S (NASDAQ:GMAB) is one of the Best Extremely Profitable Stocks to Buy Right Now. On July 16, Genmab A/S (NASDAQ:GMAB) announced new sales figures for DARZALEX as of the second quarter of 2025...
Truist Securities Hikes Genmab A/S (GMAB) Price Target Buoyed by Revenue Outlook
Genmab A/S (NASDAQ:GMAB) is one of the best biotech stocks to buy according to billionaire Steve Cohen.
10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen
Steve Cohen, whose success at SAC Capital made him one of the most successful hedge fund managers on Wall Street, is a worried man.
11 Best Undervalued Stocks to Invest in Now
David Kostin, the Chief US Equity Strategist at Goldman Sachs Research, stated that in addition to the improved interest rate outlook, the Q1 2025 earnings results were strong, which increased confidence...
Billionaire Hedge Funds
